Overall, the first‐line EGFR TKI therapy followed by TRT before the onset of secondary resistance to TKI showed better efficacies in patients with oligometastatic EGFRm NSCLC (Table 1), but whether this could bring survival benefits need to be verified by large‐scaled prospective randomized trials. Here, EGFR is linked to non-small cell lung carcinoma.